Restorative <br> Heart Valve Therapy<i class=">

Restorative
Heart Valve Therapy

 

Xeltis is a clinical-stage medical device company pioneering a restorative approach in heart valve therapy.

Xeltis’ heart valves enable the patient’s own body to naturally restore a new heart valve through a therapeutic approach called Endogenous Tissue Restoration (ETR).

Series C

€45M Funding: The largest investment round for a private medical device company in Europe in 2017

<a href=Series C">

ETR

With ETR, the patient’s natural healing system develops tissue that pervades Xeltis’ heart valve, forming a new, natural and fully functional valve within it. As ETR occurs, Xeltis implants are gradually absorbed by the body. ETR is enabled by the porous structure of Xeltis’ heart valves, which are made of bioabsorbable polymers, based on Nobel-prize awarded science.

LEARN MORE

Key Benefits

01

Xeltis’ restorative heart valves may help overcome the limitations of current artificial valves.

02

Xeltis devices may help reduce the need for:
• repeated replacement procedures
• long-term medication with their potentially severe side effects.

03

Xeltis devices may help improve quality of life for patients with heart valve replacement.

04

Xeltis heart valve therapy may help reduce the overall cost of heart valve disease treatment.

Clinical Milestones

Feasibility studies of RestoreX technology with pediatric patients completed two-years follow-up.

Xeltis pediatric pulmonary valve, its anticipated first commercial product, is in clinical trials.

Xeltis aortic valve is in pre-clinical trials stage.

Nobel Prize Awarded Science

Xeltis’ cardiovascular implants are made of bioabsorbable polymers based on Nobel Prize awarded science of supramolecular chemistry by Jean-Marie Lehn – Xeltis Scientific Advisor.

The Future
of Heart Valve
Replacement

CTO and co-Founder Martijn
Cox takes you into the lab
for a closer look at Xeltis. WATCH THE VIDEO